Reply of the Authors: Safety and pharmacology of AMY109, a long-acting anti-interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial

This item is an authors' reply accompanying a phase 1 trial of AMY109, a long-acting anti-interleukin-8 antibody being investigated for endometriosis. The provided text contains only author contribution statements and conflict-of-interest disclosures: several co-authors are employees, shareholders, or patent inventors associated with Chugai Pharmaceutical Co., Ltd., which funded the underlying work, and one author is named on the anti-IL-8 antibody and endometriosis patents (rights assigned to Chugai). No scientific methods, results, or substantive reply content are included in the body available here, so the safety and pharmacology findings being defended cannot be paraphrased. This paper is centrally about endometriosis — it is an authors' reply defending a phase 1 safety and pharmacology trial of an anti-IL-8 antibody (AMY109) developed as a candidate endometriosis therapy.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works